Respiratory Syncytial Virus (RSV) is an easily transmittable virus that effects the lungs and airways, with symptoms similar to the flu or COVID-19. RSV infection represents a potential medical emergency for the young and the old. Right now, there are no approved vaccine options. Research studies can lead to impressive medical milestones like developing the first RSV vaccine. Our participant volunteers play a vital role in making that happen.

Nothing excites us more than talking with one of our patients. We asked retired Obstetrician Dr. Michael Hoffman, who participated in an RSV vaccine study, to answer a few questions for us. This is what he had to say.

Why did you chose to participate in an RSV vaccine research study?

RSV is important to me because, as an Obstetrician, I’ve delivered many babies. About 20 years ago, when I asked mothers how their baby was, some would say it was in ICU due to a new virus called RSV. That was the first I heard of it. Clinical research is important because it's the only way to prove that what you think is happening is actually happening and working. Vaccines make a huge difference in who gets the disease. I thought if we could prevent people from getting RSV and dying from it; I’m all for that! When Accellacare called me for a study on RSV and said they had a vaccine to prevent it, I said, "Sign me up!"

Why did you participate with Accellacare? 

When I met the staff, they were so kind and nice to me. The organization was so well put together; I had to sign up.

What was your participation experience like? 

I like Accellacare because the follow up is very good. The emails and text I got were very exact and easy to follow.

Dr. Hoffman has been a part of developing an RSV vaccine that aims to provide protection from RSV virus that puts many infants and seniors at risk for severe infection. If you are interested in joining him in the process of developing an RSV vaccine, consider joining our study. You can sign up to learn more today here.